Joshua T Kantrowitz (Joshua Kantrowitz)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 13

Top Topics

Randomized Controlled Trial

Transcranial Direct Current Stimulation

Top Venues

The international journal of neuropsychopharmacology

Journal of clinical psychopharmacology

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Petros D Petridis, Ari B Jaffe, Joshua T Kantrowitz, Jack Grinband
Tardive Dyskinesia Suppressed With Ginkgo Biloba. Journal of clinical psychopharmacology (2023)
Petros D Petridis, Ari B Jaffe, Joshua T Kantrowitz, Jack Grinband
Tardive Dyskinesia Suppressed With Ginkgo Biloba. Journal of clinical psychopharmacology 43 (6) (2023)
Joshua T Kantrowitz, Christoph U Correll, Rakesh Jain, Andrew J Cutler
New Developments in the Treatment of Schizophrenia: An Expert Roundtable. The international journal of neuropsychopharmacology (2023)
Viraj Govani, Adithya Shastry, Daniel Iosifescu, Preetika Govil, Megan Mayer, Tarek Sobeih, Tse Choo, Melanie Wall, Pejman Sehatpour, Joshua T Kantrowitz
Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study. Research square (2023)
Elizabeth Deckler, Melissa Ferland, Stephanie Brazis, Megan R Mayer, Marlene Carlson, Joshua T Kantrowitz
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting. The international journal of neuropsychopharmacology 25 (11) (2022)
Ondine Adam, Martin Blay, Andre R Brunoni, Hsin-An Chang, July S Gomes, Daniel C Javitt, Do-Un Jung, Joshua T Kantrowitz, Sanne Koops, Jean-Pierre Lindenmayer, Ulrich Palm, Robert C Smith, Iris E Sommer, Leandro do Costa Lane Valiengo, Thomas W Weickert, Jérôme Brunelin, Marine Mondino
Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Schizophrenia bulletin 48 (6) (2022)
Joshua T Kantrowitz
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. CNS drugs 35 (11) (2021)
Joshua T Kantrowitz
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. CNS drugs 34 (9) (2021)
Joshua T Kantrowitz
Additional perspective on cariprazine and negative symptoms. Expert opinion on pharmacotherapy (2021)
Joshua T Kantrowitz
How do we address treating the negative symptoms of schizophrenia pharmacologically? Expert opinion on pharmacotherapy 22 (14) (2021)
Pejman Sehatpour, Daniel C Javitt, Heloise M De Baun, Marlene Carlson, Anna Beloborodova, David H Margolin, Mark B L Carlton, Nicola L Brice, Joshua T Kantrowitz
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2021)
Joshua T Kantrowitz, Zhengchao Dong, Matthew S Milak, Rain Rashid, Lawrence S Kegeles, Daniel C Javitt, Jeffrey A Lieberman, J John Mann
Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. Translational psychiatry 11 (1) (2021)
Amir M Meftah, Elizabeth Deckler, Leslie Citrome, Joshua T Kantrowitz
New discoveries for an old drug: a review of recent olanzapine research. Postgraduate medicine 132 (1) (2020)